IMR Press / FBL / Volume 11 / Issue 1 / DOI: 10.2741/1775

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Immunotherapy as part of a multidisciplinary approach to melanoma treatment
Show Less
1 H. Lee Moffitt Cancer Center and Research Institute, Cutaneous Oncology, 12902 Magnolia Drive, Tampa, Florida, 33612
2 H. Lee Moffitt Cancer Center and Research Institute, Molecular Oncology Program, 12902 Magnolia Drive, Tampa, Florida, 33612
Academic Editor:Q. Ping Dou
Front. Biosci. (Landmark Ed) 2006, 11(1), 1–14; https://doi.org/10.2741/1775
Published: 1 January 2006
(This article belongs to the Special Issue Potential molecular targets for chemoprevention)
Abstract

We have made tremendous advances in the earlier diagnosis and treatment of melanoma. Indeed, the early recognition and surgical management of thin primary cutaneous melanoma of <1.00 mm in Breslow's thickness has resulted in a >97% cure rate (1). For stage III and IV disease, our current treatment options are poor, with response rates well below 20% and only rare long-term responders noted (2-3). This is most clearly highlighted in a recent review by Rosenberg et al. who examined the role of immunotherapy in the treatment of patients with stage IV melanoma over a nine-year period (4). Overall, 96% of all patients had metastatic melanoma, utilizing a wide array of vaccine strategies including synthetic peptides, naked DNA, dendritic cells (DC) and recombinant viruses in patients with various advanced malignancies. They found that the overall objective response rate, utilizing conventional oncologic criteria for clinical tumor response, was only 2.6%. (4). By combining the results of the Surgery Branch with the latter trials above, a total of 1,306 vaccine treatments have been given for an overall objective response rate of 3.3%. Such dismal results compel us to take a critical look at our current approach to tumor immunology and immunotherapy, with the intention of improving our current understanding of the complex interactions that occur within the tumor microenvironment. This in turn will provide us with new insight and direction as we design the next generation of vaccines for patients with advanced cancer and in particular melanoma.

Share
Back to top